Session Type
Meeting
Search Results for Thrombosis
Abstract Number: 107
SHM Converge 2021
Background: The risk of thrombosis and bleeding in hospitalized patients with Coronavirus disease 2019 (COVID-19) is uncertain. Early studies suggested patients with COVID-19 may develop a unique coagulopathy marked by elevated thrombotic risk which has led some institutions to recommend stronger thromboprophylaxis in these patients. Our goal was to quantify the incidence of thrombosis and […]
Abstract Number: 144
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 145
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 154
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: The position of the tip of a peripherally inserted central catheter (PICC) is associated with deep vein thrombosis (DVT). Optimal position of the tip is the cavoatrial junction; more proximal tip positions are associated with greater risk of DVT. EKG-guidance has recently emerged as a modality to ensure proper tip position. Compared to chest […]
Abstract Number: 167
SHM Converge 2024
Background: Compared to peripherally inserted central catheters (PICC), midlines have a lower risk of bloodstream infection, but several studies have found increased thrombosis risk for a variety of clots such as deep vein thrombosis, superficial vein thrombosis, and greater daily hazard of thrombosis. Given increased midline use, better safety data is needed for complications such […]
Abstract Number: 172
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Since being introduced in the 1950s, midlines have since gained attention as an intravascular access option—particularly in patients requiring intravenous (IV) therapy for extended time periods. They provide an alternative to frequent venipuncture from peipheral intravenous catheters (PIV) and may reduce cost and increase patient satisfaction. The CDC and MAGIC guidelines currently recommend the […]
Abstract Number: 175
SHM Converge 2023
Background: The Michigan PICC-DVT Risk Score (MRS) identified five predictors for deep venous thrombosis (DVT) associated with peripherally inserted central catheters (PICCs): presence of another central venous catheter (CVC) when device is placed, white blood cell (WBC) count at time of insertion, active cancer, number of catheter lumens, and history of venous thromboembolism (VTE)1. We […]
Abstract Number: 185
Hospital Medicine 2020, Virtual Competition
Background: Peripherally inserted central catheters (PICCs) are frequently used to deliver intravenous (IV) antibiotic therapy. Infectious disease (ID) physicians are often consulted prior to PICC placement, but whether their engagement influences PICC appropriateness and complications is not known. Methods: Using data from the Michigan Hospital Medicine Safety Consortium on PICCs placed in hospitalized medical patients […]
Abstract Number: 214
Hospital Medicine 2020, Virtual Competition
Background: Until the advent of novel oral anticoagulants (NOACs), Warfarin was the only oral agent available for the treatment of deep venous thrombosis (DVT) and Pulmonary embolism (PE). Bridging with parenteral anticoagulation until warfarin reaches a full therapeutic level often results in prolonged hospitalization. Rivaroxaban, Dabigatran, Apixaban, Edoxaban were approved by the FDA for DVT […]
Abstract Number: 221
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: The venous thromboembolism (VTE) rate in patients with current or recent hospitalization is 330/100,000 person-year vs. 8/100,000 in outpatients. Hence, hospitalists often assess risk and pursue a diagnosis of VTE in their patients. Lower extremity (LE) DVT risk prediction tools such as the Wells score perform poorly on inpatients and hospitalist specific guidelines for […]